ARTICLE | Financial News
Woodford backs AMO in $25M series A round
October 1, 2015 1:02 AM UTC
AMO Pharma Ltd. (London, U.K.) raised $25 million in a series A round from Woodford Investment Management through its Woodford Patient Capital Trust plc (LSE:WPCT) fund.
AMO plans to begin Phase I/IIa testing next year of lead candidate AMO-02 to treat myotonic dystrophy type 1 (DM1, Steinert's disease) and AMO-01 to treat fragile X syndrome. ...